Previous 10 | Next 10 |
2023-11-24 13:37:41 ET Celularity ( NASDAQ: CELU ) on Friday said it has received notification from Nasdaq stating that the company is not in compliance with continued listing requirements due to failure to timely file a Form 10-Q for third quarter of 2023. The company is requ...
FLORHAM PARK, N.J., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today that on November 21, 2023, the Company received notification from the Listing ...
Impac Mortgage Holdings, Inc. (IMPM) is expected to report for quarter end 2023-09-30 Westbury Bancorp Inc (WBBW) is expected to report for quarter end 2023-09-30 Aldeyra Therapeutics Inc. (ALDX) is expected to report $-0.24 for Q3 2023 Zalando SE ADR (ZLNDY) is expected to report for...
thyssenkrupp AG (TYEKF) is expected to report for Q4 2023 Azul S.A. American Depositary Shares (each representing three preferred shares) (AZUL) is expected to report $-0.38 for Q3 2023 Bath & Body Works Inc. (BBWI) is expected to report $0.36 for Q3 2024 Johnson Controls Internat...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Celularity Inc. (CELU) is expected to report $-0.03 for Q3 2023
SFDA Classification Establishes Clear Regulatory Pathway for Importation of Celularity’s Commercial Biomaterial Products into the Kingdom of Saudi Arabia FLORHAM PARK, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company d...
2023-10-11 08:30:48 ET More on Celularity Celularity announces $3M registered direct offering, stock up 8% Seeking Alpha’s Quant Rating on Celularity Historical earnings data for Celularity Financial information for Celularity For further detai...
FLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D...
2023-08-29 09:10:07 ET More on Celularity Celularity announces $3M registered direct offering, stock up 8% Seeking Alpha’s Quant Rating on Celularity Earnings data for Celularity For further details see: Celularity announces multi-year research col...
News, Short Squeeze, Breakout and More Instantly...
For the first quarter 2024, Celularity expects combined net sales of $14.8 million for its advanced biomaterial product and biobanking businesses, compared to the $10.25 million to $11.5 million guidance range previously announced in February. Celularity’s expected com...
3D Systems Corporation (DDD) is expected to report $-0.11 for Q1 2024 ZW Data Action Technologies Inc. (CNET) is expected to report for Q1 2024 Celularity Inc. (CELU) is expected to report for Q1 2023 DMK Pharmaceuticals Corporation (DMKPQ) is expected to report for Q1 2024 Atlant...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...